CymaBay Therapeutics, Inc. (CBAY) Research
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Market snapshot
- Symbol
- CBAY
- Price
- $32.48
- Day change
- +0.03%
- Market cap
- $3.7B
- P/E ratio
- -32.74x
- 52-week range
- 7.261-32.5
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- Loewy Caroline M — D-Return (32000 shares) on 2024-03-22
- Loewy Caroline M — D-Return (30000 shares) on 2024-03-22
- Loewy Caroline M — D-Return (15000 shares) on 2024-03-22
- Loewy Caroline M — D-Return (7500 shares) on 2024-03-22
- Loewy Caroline M — D-Return (16000 shares) on 2024-03-22
Open CymaBay Therapeutics, Inc. (CBAY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.